{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Rate of MRD negativity after 12 months of treatment with Ixazomib in combination with lenalidomide and dexamethasone compared to MRD negativity rate after 12 months of lenalidomide alone. For the majority of patients, where MRD positivity at screening will be determined by Multi-parameter Flow Cytometry (MFC), an improvement will be defined as a conversion from MRD-positive to MRD-negative disease by MFC. Additionally, in the fraction of patients with MRD-negative disease by MFC at screening, who were MRD-positive by Next Generation Sequencing (NGS), an improvement will be defined as a conversion from MRD-positive to MRD-negative disease by NGS","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nDexamethasone: Given PO","id":"OG000","title":"Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)"},{"description":"Patients receive lenalidomide PO as in Arm I.\n\nLenalidomide: Given PO","id":"OG001","title":"Arm II (Lenalidomide)"}],"paramType":"NUMBER","populationDescription":"The data for 3 patients in Arm 1 AND 4 patients in Arm II were not collected.","reportingStatus":"POSTED","timeFrame":"At 12 months","title":"Percentage of Participants With MRD Negativity","type":"PRIMARY","unitOfMeasure":"percentage of participants"}